These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25343149)

  • 21. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peripherally acting therapies for the treatment of irritable bowel syndrome.
    Saad RJ
    Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
    Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron).
    Goldberg PA; Kamm MA; Setti-Carraro P; van der Sijp JR; Roth C
    Digestion; 1996; 57(6):478-83. PubMed ID: 8913711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding and treating an irritable bowel.
    Harv Womens Health Watch; 2004 Apr; 11(8):1-3. PubMed ID: 15100057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy for irritable bowel syndrome.
    Lacy BE
    N Engl J Med; 2004 Mar; 350(12):1261-3; author reply 1261-3. PubMed ID: 15031865
    [No Abstract]   [Full Text] [Related]  

  • 27. Renzapride in IBS: is efficacy in the eye of the beholder?
    Ford AC
    Aliment Pharmacol Ther; 2010 Jul; 32(1):113-4; author reply 114-5. PubMed ID: 20597877
    [No Abstract]   [Full Text] [Related]  

  • 28. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J; Zakari M; Lembo AJ
    Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irritable bowel syndrome.
    Mertz HR
    N Engl J Med; 2003 Nov; 349(22):2136-46. PubMed ID: 14645642
    [No Abstract]   [Full Text] [Related]  

  • 32. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
    Shiotani A; Kusunoki H; Ishii M; Imamura H; Manabe N; Kamada T; Hata J; Merchant JL; Haruma K
    Neurogastroenterol Motil; 2015 Jan; 27(1):82-91. PubMed ID: 25428414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irritable bowel syndrome.
    Kennedy T; Rubin G; Jones R
    Clin Evid; 2004 Dec; (12):683-92. PubMed ID: 15865669
    [No Abstract]   [Full Text] [Related]  

  • 35. Emerging pharmacological therapies for the irritable bowel syndrome.
    Maneerattanaporn M; Chang L; Chey WD
    Gastroenterol Clin North Am; 2011 Mar; 40(1):223-43. PubMed ID: 21333909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy for irritable bowel syndrome.
    Olden KW
    N Engl J Med; 2004 Mar; 350(12):1261-3; author reply 1261-3. PubMed ID: 15028836
    [No Abstract]   [Full Text] [Related]  

  • 39. "Pre-cebo": an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials.
    Kim SE; Kubomoto S; Chua K; Amichai MM; Pimentel M
    J Clin Gastroenterol; 2012 Sep; 46(8):686-90. PubMed ID: 22739219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms.
    Shah ED
    Aliment Pharmacol Ther; 2023 Jun; 57(11):1335-1336. PubMed ID: 37161628
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.